| scholarly article | Q13442814 |
| P2093 | author name string | Murugesan Rajeswari | |
| Natchimuthu Santhi | |||
| Vembu Bhuvaneswari | |||
| P2860 | cites work | Janus kinases in immune cell signaling | Q24322021 |
| Janus kinase deregulation in leukemia and lymphoma | Q26991810 | ||
| 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models | Q27683554 | ||
| Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors | Q27684317 | ||
| Naphthyl ketones: a new class of Janus kinase 3 inhibitors | Q28374755 | ||
| Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes | Q29616736 | ||
| Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening | Q29617343 | ||
| Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes | Q34132778 | ||
| JAK3 specific kinase inhibitors: when specificity is not enough. | Q34173476 | ||
| PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results | Q34584338 | ||
| JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. | Q34595205 | ||
| The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo | Q34989826 | ||
| Janus kinase-3 dependent inflammatory responses in allergic asthma | Q35031161 | ||
| Jak3 and the pathogenesis of severe combined immunodeficiency | Q35818891 | ||
| A new modality for immunosuppression: targeting the JAK/STAT pathway | Q35825869 | ||
| ZINCPharmer: pharmacophore search of the ZINC database | Q36088378 | ||
| Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). | Q39798321 | ||
| Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3). | Q40190215 | ||
| Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog | Q42109929 | ||
| 2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors. | Q43259921 | ||
| Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice | Q44410698 | ||
| The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models | Q44695040 | ||
| JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. | Q45930112 | ||
| Binding mode prediction of cytochrome p450 and thymidine kinase protein-ligand complexes by consideration of water and rescoring in automated docking. | Q46414034 | ||
| Modeling water molecules in protein-ligand docking using GOLD. | Q46725683 | ||
| Docking of aminoglycosides to hydrated and flexible RNA. | Q51631377 | ||
| A specific inhibitor of janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis | Q73329964 | ||
| Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice | Q74420476 | ||
| Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3 | Q80171440 | ||
| 3D-QSAR and molecular docking studies of 1,3,5-triazene-2,4-diamine derivatives against r-RNA: novel bacterial translation inhibitors | Q80971151 | ||
| Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate | Q84127900 | ||
| P433 | issue | 3 | |
| P921 | main subject | virtual screening | Q4112105 |
| P304 | page(s) | 157-163 | |
| P577 | publication date | 2014-03-19 | |
| P1433 | published in | Bioinformation | Q27721200 |
| P1476 | title | Pharmacophore and Virtual Screening of JAK3 inhibitors | |
| P478 | volume | 10 |
| Q91726846 | Construction of Quantitative Structure Activity Relationship (QSAR) Models to Predict Potency of Structurally Diversed Janus Kinase 2 Inhibitors | cites work | P2860 |
Search more.